Landaas & Co. WI ADV Decreases Position in AbbVie Inc. (ABBV)

Landaas & Co. WI ADV lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,049 shares of the company’s stock after selling 795 shares during the quarter. AbbVie makes up 1.0% of Landaas & Co. WI ADV’s portfolio, making the stock its 10th biggest position. Landaas & Co. WI ADV’s holdings in AbbVie were worth $1,165,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ABBV. Los Angeles Capital Management & Equity Research Inc. raised its holdings in AbbVie by 24.5% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 740,392 shares of the company’s stock worth $53,686,000 after purchasing an additional 145,691 shares in the last quarter. Spectrum Management Group Inc. grew its stake in shares of AbbVie by 11.5% in the second quarter. Spectrum Management Group Inc. now owns 28,100 shares of the company’s stock worth $2,038,000 after acquiring an additional 2,892 shares during the last quarter. AGF Investments America Inc. grew its stake in shares of AbbVie by 3.6% in the second quarter. AGF Investments America Inc. now owns 29,064 shares of the company’s stock worth $2,107,000 after acquiring an additional 1,017 shares during the last quarter. Ffcm LLC grew its stake in shares of AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after acquiring an additional 963 shares during the last quarter. Finally, Fiduciary Trust Co. grew its stake in shares of AbbVie by 3.2% in the second quarter. Fiduciary Trust Co. now owns 321,953 shares of the company’s stock worth $23,345,000 after acquiring an additional 10,113 shares during the last quarter. Institutional investors and hedge funds own 70.57% of the company’s stock.

A number of equities research analysts have recently commented on the company. Argus increased their target price on AbbVie from $120.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Zacks Investment Research cut AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. BMO Capital Markets cut AbbVie from a “market perform” rating to an “underperform” rating and cut their target price for the stock from $125.86 to $84.00 in a research note on Monday, January 29th. They noted that the move was a valuation call. Bank of America set a $120.00 target price on AbbVie and gave the stock a “hold” rating in a research note on Monday, March 26th. Finally, Barclays cut their target price on AbbVie from $120.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 5th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $118.02.



AbbVie stock opened at $93.64 on Thursday. The company has a debt-to-equity ratio of 6.07, a quick ratio of 1.18 and a current ratio of 1.28. AbbVie Inc. has a one year low of $63.12 and a one year high of $125.86. The firm has a market cap of $143,679.80, a P/E ratio of 16.72, a price-to-earnings-growth ratio of 0.86 and a beta of 1.61.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.44 by $0.04. AbbVie had a return on equity of 158.15% and a net margin of 18.82%. The company had revenue of $7.74 billion for the quarter, compared to analysts’ expectations of $7.53 billion. During the same period last year, the firm posted $1.20 earnings per share. AbbVie’s revenue was up 13.9% compared to the same quarter last year. equities analysts anticipate that AbbVie Inc. will post 7.51 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be given a dividend of $0.96 per share. The ex-dividend date is Thursday, April 12th. This is a boost from AbbVie’s previous quarterly dividend of $0.71. This represents a $3.84 annualized dividend and a dividend yield of 4.10%. AbbVie’s dividend payout ratio (DPR) is 50.71%.

AbbVie declared that its Board of Directors has initiated a stock repurchase program on Thursday, February 15th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

In other AbbVie news, EVP Carlos Alban sold 83,574 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $114.49, for a total value of $9,568,387.26. Following the transaction, the executive vice president now directly owns 133,026 shares of the company’s stock, valued at $15,230,146.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert A. Michael sold 992 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $120.31, for a total value of $119,347.52. The disclosure for this sale can be found here. Insiders have sold 211,197 shares of company stock worth $24,585,575 over the last ninety days. 0.07% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Landaas & Co. WI ADV Decreases Position in AbbVie Inc. (ABBV)” was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://dakotafinancialnews.com/2018/04/12/landaas-co-wi-adv-decreases-position-in-abbvie-inc-abbv.html.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply